| First Author | Surace L | Year | 2015 |
| Journal | Immunity | Volume | 42 |
| Issue | 4 | Pages | 767-77 |
| PubMed ID | 25888260 | Mgi Jnum | J:229777 |
| Mgi Id | MGI:5754451 | Doi | 10.1016/j.immuni.2015.03.009 |
| Citation | Surace L, et al. (2015) Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 42(4):767-77 |
| abstractText | Radiotherapy induces DNA damage and cell death, but recent data suggest that concomitant immune stimulation is an integral part of the therapeutic action of ionizing radiation. It is poorly understood how radiotherapy supports tumor-specific immunity. Here we report that radiotherapy induced tumor cell death and transiently activated complement both in murine and human tumors. The local production of pro-inflammatory anaphylatoxins C3a and C5a was crucial to the tumor response to radiotherapy and concomitant stimulation of tumor-specific immunity. Dexamethasone, a drug frequently given during radiotherapy, limited complement activation and the anti-tumor effects of the immune system. Overall, our findings indicate that anaphylatoxins are key players in radiotherapy-induced tumor-specific immunity and the ensuing clinical responses. |
